Gilead Sciences Korea announced on the 18th that it has launched its metastatic triple-negative breast cancer drug ‘Trodelvy (sacituzumab govitecan)’ in Korea.

Until now, Trodelvy has been supplied through the Korea Orphan & Essential Drug Center, but from the 18th, Gilead will supply it domestically, and patients will be able to use it with prescriptions at hospitals.

Trodelvy, a Trop-2 targeting antibody-drug conjugate (ADC), consists of a monoclonal antibody that binds to the cell surface antigen Trop-2 and a TOP1 inhibitor payload ‘SN-38’ that destroys cancer cells.

By targeting only Trop-2, which is highly expressed in various types of cancers, including m